Ovid reports Q1 net loss $16.1M, revenue $1.4M; OV329 IND on track for Q4 2022

Ovid Therapeutics Inc.

2022-Q1 EPS reported -$0.23 revenue$1,445,366

Net loss $16.1M ($0.23/sh) vs net income $176M in Q1 2021 on one-time Takeda payment.
Revenue fell to $1.4M from $208.4M; current revenue from Marinus and Healx license fees.
Cash and equivalents $166.7M expected to fund pipeline into 2025.
IND for OV329 (GABA aminotransferase inhibitor) planned in Q4 2022 to start Phase 1.
Non-GAAP adjusted operating expenses were $14.2M; total operating expenses $17.7M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.